Incremental value of cardiovascular magnetic resonance imaging in family screening for hypertrophic cardiomyopathy
Autor: | R P J Budde, Michelle Michels, Arend F.L. Schinkel, H.C Hassing, Roy Huurman, Alexander Hirsch, M. van Slegtenhorst, Judith M.A. Verhagen, N. van der Velde |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
medicine.diagnostic_test business.industry Hypertrophic cardiomyopathy Magnetic resonance imaging General Medicine medicine.disease Left ventricular hypertrophy Linear gingival erythema Internal medicine ECG normal cardiovascular system Medical imaging Cardiology Medicine Echocardiography transthoracic Radiology Nuclear Medicine and imaging cardiovascular diseases Cardiology and Cardiovascular Medicine business Value (mathematics) |
Zdroj: | European Heart Journal - Cardiovascular Imaging. 22 |
ISSN: | 2047-2412 2047-2404 |
DOI: | 10.1093/ehjci/jeaa356.389 |
Popis: | Funding Acknowledgements Type of funding sources: None. Genetic testing in relatives of hypertrophic cardiomyopathy (HCM) patients can lead to early identification of carriers of pathogenic DNA variants (G+), before onset of left ventricular hypertrophy (LVH). Repeated evaluation by electrocardiography (ECG) and transthoracic echocardiography (TTE) is recommended to detect HCM during follow-up. Cardiovascular magnetic resonance (CMR) imaging has become valuable in the work-up of HCM, although its role in G+ subjects has not been extensively evaluated. In this study, we investigated the value of CMR in the G+/LVH- population. We included 55 G+ subjects who underwent CMR in addition to ECG and TTE, with a maximal wall thickness (MWT) An overview of ECG/TTE and CMR findings is shown in the Figure. Two of 16 (13%) subjects diagnosed with HCM on TTE were reclassified as having no HCM on CMR, and 8 of 39 (21%) subjects without HCM on TTE were reclassified as HCM on CMR. These 8 subjects had a mean MWT of 15.4 ± 2.6 mm on CMR and a mean MWT difference of 4.5 ± 2.9 mm (range 1.7-9.4) compared to TTE, which in 3 cases was explained by a hook-shaped thickening of the basal anterior wall in the 2 chamber view, not visible on TTE. Compared to subjects without HCM on both modalities, the reclassified group had a significantly higher QRS duration (104 ± 14 vs 93 ± 11 ms, p = 0.03) and anterior mitral valve leaflet length (30 ± 4 vs 26 ± 3 mm, p = 0.01). Of the 13 subjects with normal ECG/TTE results, none were reclassified as HCM using CMR. The proportion of additional CMR abnormalities was large in subjects with and without abnormal ECG/TTE results (57% vs 38%, p = 0.24). Subjects with poor TTE image quality were equally likely to be reclassified compared to those with sufficient image quality (10% vs 24%, p = 0.19). Logistic regression demonstrated that the presence of TTE/ECG abnormalities (odds ratio [OR] 8.7 [1.3-59.0], p = 0.03) and age (OR 1.1 [1.0-1.2], p Additional CMR imaging reclassifies 18% of subjects. Subjects with normal ECG and TTE results are not diagnosed as HCM on CMR, but the prevalence of HCM-related abnormalities on CMR was high in subjects with and without ECG/TTE abnormalities. Abstract Figure. Diagnostic approach and CMR findings |
Databáze: | OpenAIRE |
Externí odkaz: |